Association of ring box-1 protein overexpression with clinicopathologic prognostic parameters in prostate carcinoma

Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis

“…[ 5 ] ROC1 is reported to be overexpressed in a variety of neoplasms, including liver cancer, gastric cancer, esophageal cancer, bladder cancer, non-small cell lung cancer, renal cell carcinoma (RCC), prostate cancer, ovarian cancer and melanoma. [ 5 , 12 , 15 , 25 , 26 ] Thereby we conducted this meta-analysis to explore the potential connection between ROC1 expression and its prognostic values in cancers. Our results showed that ROC1 was able to serve as a potential prognostic biomarker in multiple tumors.…”

“…[ 6 ] Celik et al have demonstrated that overexpression of ROC1 is associated with advanced clinical stage and high prostate specific antigen (PSA) levels in prostate cancer patients and depletion of ROC1 crucially induces apoptosis, senescence, autophagy and G2/M arrest in prostate cancer cells. [ 12 ] Several studies have indicated that overexpression of ROC1 is connected with higher Fuhrman grade and ROC1silencing remarkably hinders cancer cells growth and survival through G2/M arrest, senescence and apoptosis by accumulation of WEE1, p21, p27, NOXA, and BIM in renal cell carcinoma (RCC). [ 14 , 25 ] Elevated ROC1 expression is associated with poor clinical features in ovarian cancer and reduced expression of ROC1 can inhibit ovarian cancer cells proliferation via ubiquitination of TP53 through the miR-194-5p/ROC1 pathway, finally blocking cancer cells growth and invasion.…”

“…On the other hand, increased ROC1 expression is associated with large tumor size, lymph node metastasis (LNM) and Tumor Node Metastasis (TNM) stage in a diversity of neoplasms. [6,8,10,[12][13][14][15] So elevated expression of ROC1 could be a potential biomarker for identifying patients with poor prognostic factors and advanced clinical features, serving as a potential target for cancer therapy. [9,11,16] Due to the limited sample size in present studies, we carried out this meta-analysis to elucidate the association of ROC1 between the prognosis and clinicopathologic characteristics in cancer patients, thus estimating the potential value of ROC1 as a promising prognostic predictor in human tumors.…”